The Road to Cures Through Immunotherapy and Precision Medicine. Series of 5 Modules

Activity Overview

This activity provides learners with an overview of the latest advancements in biology and treatments for acute myeloid leukemia, aggressive lymphoma, and myeloma. The development and practical applications for CAR T-cell therapy in blood cancers is presented. A review of data from the Leukemia & Lymphoma Society patient registry on SARS-CoV-2 vaccination and antibody response in patients with blood cancer provides a glimpse of unmet needs in this vulnerable patient population.

2.75 CE Credit(s)
Expires: March 9, 2023

Target Audience

This activity is designed to meet the educational needs of hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.

Learning Objectives

Upon successful completion of this educational activity, participants should be better able to:

  • Describe the current state of chimeric antigen receptor (CAR) T-cell therapy for hematologic malignancies. (Module 1 CME: 0.5)
  • Identify the impact of minimal residual disease (MRD) analysis and pre-leukemic clones on the treatment of acute leukemia. (Module 2 CME: 0.5)
  • Summarize the efficacy of targeted therapy in genetic subtypes of aggressive lymphoma. (Module 3 CME: 0.5)
  • Assess how novel therapeutic strategies lead to improved survival in myeloma. (Module 4 CME: 0.5)
  • Analyze the impact of COVID-19 and its effect on therapy and outcomes in blood cancer patients. (Module 5 CME: 0.75)

Activity Faculty


Larry A. Saltzman, MD

Executive Research Director
The Leukemia & Lymphoma Society
Rye Brook, NY

Anderson_300x400 (1)

Kenneth C. Anderson, MD

Kraft Family Professor of Medicine
Harvard Medical School
Program Director, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, MA


Lee M. Greenberger, PhD

Chief Scientific Officer
The Leukemia & Lymphoma Society
Rye Brook, NY

June_300x400 (1)

Carl H. June, MD

Richard W. Vague Professor, Immunotherapy
Director, Center for Cellular Immunotherapies
Director, Parker Institute for Cancer Immunotherapy
University of Pennsylvania
Perelman School of Medicine
Philadelphia, PA

Roboz_300x400 (1)

Gail J. Roboz, MD

Professor, Medicine
Director, Clinical and Translational Leukemia Program
Weill Medical College of Cornell University
Division of Hematology and Oncology
New York-Presbyterian Hospital
New York, NY


Louis M. Staudt, MD, PhD

Chief, Lymphoid Malignancies Branch
Director, Center for Cancer Genomics
National Cancer Institute
Bethesda, MD


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources